Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-13 of 13

Sort by

Sort Order Select

Journal Articles

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Jérôme Fayette, Lisa Licitra, Kevin Harrington, Robert Haddad, Lillian L. Siu, Yi-Chun Liu, Makoto Tahara, Jean-Pascal Machiels, Danny Rischin, Tanguy Y. Seiwert, Robert L. Ferris, Ulrich Keilholz, Amanda Psyrri, Bhumsuk Keam, Paolo Bossi, Robert Metcalf, Ching-Yun Hsieh, Paul M.J. Clement, Pavel Isaev, Ali Mudunov, José Dinis, Ann Hoeben, Stefan Kasper, Konrad Klinghammer, Michael Hwang, Jorge Blando, Olivier Serrano, Dario Ruscica, Roger B. Cohen, for the INTERLINK-1 investigators, Douglas R. Adkins, Lucia Aguas, Myung Ju Ahn, Yolanda Escobar Álvarez, Jessica R. Bauman, Maureen Bernadach, Federica Bertolini, Marcelo R. Bonomi, Christian Borel, Paolo Bossi, Michael Boyer, Santiago Cabezas Camarero, Tsung-Ming Chen, Wonyoung Choi, Vyacheslav Chubenko, Paul Clement, Roger B. Cohen, Anirudha Dasgupta, Amaury Daste, Helena Rodrigues de Andrade, Jan Paul de Boer, Thiago Bueno de Oliveira, Charles AJ de Padua, Jan H. Demol, Joao Dias, Andreas Dietz, José Dinis, Lara Carmen Iglesias Docampo, Lucas Vieira dos Santos, Khashayar Esfahani, Agustin Horacio Falco, Jérôme Fayette, Chistian Sebastian Fuentes, Madoka Furukawa, Danilo Galizia, Hui K. Gan, Irene Braña García, Maria Ghi, Robert I. Haddad, Simon Häfliger, Kevin Harrington, Stephanie Henry, Ann Hoeben, Yoshitaka Honma, Ching-Yun Hsieh, Pavel A. Isaev, Philipp Ivanyi, Demetria I. Jacks, Alfonso Berrocal Jaime, Michael J. Jelinek, Ana Joaquim, Ricklie Julian, Michalis Karamouzis, Stefan Kasper, Bhumsuk Keam, Charles Kelly, Sung-Bae Kim, Ji-Won Kim, Hee Kyung Kim, Naomi Kiyota, Konrad Klinghammer, Svetlana Kutukova, Simon A. Laban, Rubi K. Li, Lisa F. Licitra, Jin-Ching Lin, Yi-Chun Liu, Lorenzo Livi, Silvia Lopes, Jean-Pascal Machiels, Milena Mak, Muneyuki Masuda, Thibault Mazard, Robert L. Metcalf, Brandon M. Meyers, Aurora Mirabile, Ali Mudunov, Urs Müller-Richter, Prakash C. Neupane, Grzegorz S. Obara, Obiageli U. Ogbata, Kenji Okami, Nobuhiko Oridate, Konstantinos Papazizis, Martín Paskevicius, Dainik Patel, Konstantin Penkov, Francesco Perri, Petar Petrov, Zia Poonja, Marshall R. Posner, Rafaela Pozzobon, Katharine A. Price, Amanda Psyrri, John Querol, Justyna K. Rawluk, Danny Rischin, Sacha Rothschild, Paweł Różanowski, Rossitza Krasteva Ruseva, Sebastien Salas, Seong-Hoon Shin, Hitesh B. Singh, Lillian L. Siu, Martin Smoragiewicz, Paul L. Swiecicki, Petr Szturz, Masahiro Tabata, Makoto Tahara, Shunji Takahashi, Kaoru Tanaka, Margarida Teixeira, Clémence Toullec, Petranka P. Troyanova, Tsutomu Ueda, Charles Uy, Carla M. van Herpen, Marek Wojtukiewicz, Muh-Hwa Yang, Cheng T. Yen, Chia-Jui Yen, Tomoya Yokota, Dan P. Zandberg, Sylvie Zanetta, Bogdan A. Żurawski

Clin Cancer Res (2025) 31 (13): 2617–2627.

https://doi.org/10.1158/1078-0432.CCR-25-0073

Published: 01 July 2025

View articletitled, INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

Clin Cancer Res (2024) 30 (24): 5548–5558.

https://doi.org/10.1158/1078-0432.CCR-24-1513

Published: 16 December 2024

View articletitled, Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

Includes: Supplementary data

Journal Articles

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Clin Cancer Res (2024) 30 (8): 1488–1500.

https://doi.org/10.1158/1078-0432.CCR-23-2978

Published: 15 April 2024

View articletitled, A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Includes: Supplementary data

Journal Articles

Abstract PO-003: Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009

Clin Cancer Res (2023) 29 (18_Supplement): PO-003.

https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-003

Published: 15 September 2023

View articletitled, Abstract PO-003: Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009

Journal Articles

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, Jean-Pascal Machiels, Ben Markman, Kimberley M. Heinhuis, Michael Millward, Martijn Lolkema, Sandip Pravin Patel, Paul de Souza, Matteo Duca, Giuseppe Curigliano, Armando Santoro, Takafumi Koyama, Michelle Brown, Heather Vezina, Chunsheng He, Quincy Siu-Chung Chu

Clin Cancer Res (2022) 28 (1): 95–105.

https://doi.org/10.1158/1078-0432.CCR-21-1181

Published: 01 January 2022

View articletitled, Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

Clin Cancer Res (2021) 27 (23): 6393–6404.

https://doi.org/10.1158/1078-0432.CCR-21-0261

Published: 01 December 2021

View articletitled, Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

Includes: Supplementary data

Journal Articles

Metabolic Imaging Using Hyperpolarized Pyruvate–Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts

Lionel Mignion, Stefania Acciardo, Florian Gourgue, Nicolas Joudiou, Xavier Caignet, Rose-Marie Goebbels, Cyril Corbet, Olivier Feron, Caroline Bouzin, Patrice D. Cani, Jean-Pascal Machiels, Sandra Schmitz, Bénédicte F. Jordan

Clin Cancer Res (2020) 26 (8): 1932–1943.

https://doi.org/10.1158/1078-0432.CCR-19-1369

Published: 15 April 2020

View articletitled, Metabolic Imaging Using Hyperpolarized Pyruvate–Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts

Journal Articles

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Clin Cancer Res (2020) 26 (6): 1220–1228.

https://doi.org/10.1158/1078-0432.CCR-19-2962

Published: 13 March 2020

View articletitled, Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Includes: Supplementary data

Journal Articles

HER2 and HER3 in HPV⁺ and HPV⁻ HNSCC—Letter

Jean-Pascal Machiels, Rachel Galot, Sandra Schmitz

Clin Cancer Res (2016) 22 (7): 1825.

https://doi.org/10.1158/1078-0432.CCR-15-2688

Published: 31 March 2016

View articletitled, HER2 and HER3 in HPV+ and HPV− HNSCC—Letter

Journal Articles

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Clin Cancer Res (2014) 20 (8): 2192–2204.

https://doi.org/10.1158/1078-0432.CCR-13-2200

Published: 15 April 2014

View articletitled, A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Includes: Supplementary data

Journal Articles

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Charles J. Ryan, Mark Rosenthal, Siobhan Ng, Joshi Alumkal, Joel Picus, Gwenaëlle Gravis, Karim Fizazi, Frédéric Forget, Jean-Pascal Machiels, Sandy Srinivas, Min Zhu, Rui Tang, Kelly S. Oliner, Yizhou Jiang, Elwyn Loh, Sarita Dubey, Winald R. Gerritsen

Clin Cancer Res (2013) 19 (1): 215–224.

https://doi.org/10.1158/1078-0432.CCR-12-2605

Published: 02 January 2013

View articletitled, Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Includes: Supplementary data

Journal Articles

Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer

Peter P. Grimminger, Peter Danenberg, Kathrin Dellas, Dirk Arnold, Claus Rödel, Jean-Pascal Machiels, Karin Haustermans, Annelies Debucquoy, Vaneja Velenik, Christine Sempoux, Matej Bracko, Arnulf H. Hölscher, Robert Semrau, Dongyun Yang, Kathleen Danenberg, Heinz-Josef Lenz, Daniel Vallböhmer

Clin Cancer Res (2011) 17 (10): 3469–3477.

https://doi.org/10.1158/1078-0432.CCR-10-2273

Published: 15 May 2011

View articletitled, Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer

Journal Articles

Integration of Epidermal Growth Factor Receptor Inhibitors with Preoperative Chemoradiation

Annelies Debucquoy, Jean-Pascal Machiels, William H. McBride, Karin Haustermans

Clin Cancer Res (2010) 16 (10): 2709–2714.

https://doi.org/10.1158/1078-0432.CCR-09-1622

Published: 13 May 2010

View articletitled, Integration of Epidermal Growth Factor Receptor Inhibitors with Preoperative Chemoradiation

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Trastuzumab Deruxtecan with Nivolumab in HER2-Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study

A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Abstract PO-003: Lenvatinib with or without pembrolizumab versus chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: Phase 2 LEAP-009

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors

Metabolic Imaging Using Hyperpolarized Pyruvate–Lactate Exchange Assesses Response or Resistance to the EGFR Inhibitor Cetuximab in Patient-Derived HNSCC Xenografts

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

HER2 and HER3 in HPV⁺ and HPV⁻ HNSCC—Letter

A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Biomarkers for Cetuximab-Based Neoadjuvant Radiochemotherapy in Locally Advanced Rectal Cancer

Integration of Epidermal Growth Factor Receptor Inhibitors with Preoperative Chemoradiation

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only